Lantheus Holdings (LNTH) Capital Expenditures (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Capital Expenditures came in at $3.2 million in Q1 2026, down 44.9% year-on-year from $5.9 million in Q1 2025, and down 89.52% on a QoQ basis from $30.8 million in Q4 2025.
Lantheus Holdings (LNTH) Capital Expenditures (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Capital Expenditures data on file, last reported at $3.2 million in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 44.9% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $33.5 million, a 724.14% increase from a year earlier, with the FY2025 full-year figure at $36.1 million, up 613.5% from the prior year.
- Capital Expenditures for Q1 2026 stood at $3.2 million, down from $30.8 million in the prior quarter.
- Over the last five years, Capital Expenditures for LNTH reached as high as $47.0 million in Q3 2024 and fell as low as -$75.9 million in Q4 2024.
- Historically, Capital Expenditures has averaged $4.1 million across 5 years, with a median of $5.9 million in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 438.25% in 2023 and fell as far as 309.12% in 2023.
- Year by year, Capital Expenditures stood at $18.3 million in 2022, then slumped by 309.12% to -$38.4 million in 2023, then plunged by 97.7% to -$75.9 million in 2024, then surged by 140.57% to $30.8 million in 2025, then tumbled by 89.52% to $3.2 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $3.2 million in Q1 2026, $30.8 million in Q4 2025, and $5.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.23 Mn |
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 30.77 Mn |
| Dec 31, 2025 | 30.77 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | 5.86 Mn |
| Mar 31, 2025 | 5.86 Mn |
| Dec 31, 2024 | -75.85 Mn |
| Dec 31, 2024 | -75.85 Mn |
| Sep 30, 2024 | 47.00 Mn |
| Sep 30, 2024 | 47.00 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Dec 31, 2023 | -38.37 Mn |
| Dec 31, 2023 | -38.37 Mn |